Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

orchid healthcare (a division of orchid chemicals & pharmaceuticals ltd) - cefazolinum - pulbere pentru solutie injectabila - 1 g

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

human biologicals institute (a division of indian immunologicals limited)) - final bulk for rabies human monoclonal antibody - pulbere şi solvent pentru soluţie injectabilă - 2,5 iu

Uniunea Europeană - română - EMA (European Medicines Agency)

janssen-cilag international n.v. - telaprevir - hepatita c, cronică - antivirale pentru uz sistemic - incivo în asociere cu peginterferon alfa și ribavirină, este indicat pentru tratamentul de genotip-1 hepatita cronică c la pacienții adulți cu boală hepatică compensată (inclusiv ciroză):care sunt tratamentul naivi;care au fost tratați anterior cu interferon alfa (pegilat sau non-pegilat) în monoterapie sau în asociere cu ribavirină, inclusiv relapsers, prezentat răspuns parțial și răspuns nul.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - ciprofloxacinum - soluţie perfuzabilă - 2 mg/ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - metronidazolum - soluţie perfuzabilă - 5 mg/ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - combinaţie - sirop - -

Uniunea Europeană - română - EMA (European Medicines Agency)

biontech manufacturing gmbh - single-stranded, 5’-capped messenger rna produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vaccinuri - comirnaty 30 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older.  comirnaty 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty original/omicron ba. 1 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older who have previously received at least a primary vaccination course against covid-19. comirnaty original/omicron ba. 4-5 (15/15 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty original/omicron ba. 4-5 (5/5 micrograms)/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years.  comirnaty original/omicron ba. 4-5 (1. 5/1. 5 micrograms)/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years.  comirnaty omicron xbb. 5 30 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in individuals 12 years of age and older. comirnaty omicron xbb. 5 10 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 10 micrograms/dose dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in children aged 5 to 11 years. comirnaty omicron xbb. 5 3 micrograms/dose concentrate for dispersion for injection is indicated for active immunisation to prevent covid-19 caused by sars-cov-2, in infants and children aged 6 months to 4 years. utilizarea acestui vaccin ar trebui să fie în conformitate cu recomandările oficiale.

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - ciprofloxacinum - soluţie perfuzabilă - 2 mg/ml

Republica Moldova - română - AMDM (Agenţia Medicamentului şi Dispozitivelor Medicale)

unique pharmaceutical laboratories (a division of j.b. chemicals & pharmaceuticals ltd.) - metronidazolum - soluţie perfuzabilă - 5 mg/ml

Uniunea Europeană - română - EMA (European Medicines Agency)

vetoquinol - tulatromicina - antibacteriene pentru uz sistemic - cattle; pigs; sheep - cattle: treatment and metaphylaxis of bovine respiratory disease (brd) associated with mannheimia haemolytica, pasteurella multocida, histophilus somni and mycoplasma bovis susceptible to tulathromycin. prezența bolii în efectiv trebuie stabilită înainte de tratamentul metafilactic. treatment of infectious bovine keratoconjunctivitis (ibk) associated with moraxella bovis susceptible to tulathromycin. pigs: treatment and metaphylaxis of swine respiratory disease (srd) associated with actinobacillus pleuropneumoniae, pasteurella multocida, mycoplasma hyopneumoniae, haemophilus parasuis and bordetella bronchiseptica susceptible to tulathromycin. prezența bolii în efectiv trebuie stabilită înainte de tratamentul metafilactic. the product should only be used if pigs are expected to develop the disease within 2–3 days. ovine: tratamentul etapelor timpurii ale subermatitei infecțioase (putregai picior) asociată cu dichelobacter nodosus virulent care necesită tratament sistemic.